The 5 most recent market catalysts affecting $ANAB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target
This 8-K filing discloses that HC Wainwright & Co. has reaffirmed its 'Buy' rating and $95 price target for AnaptysBio (ANAB). This is a routine analyst action that signals continu…
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 55
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81
Leerink Partners analyst David Risinger maintained an 'Outperform' rating on AnaptysBio (ANAB) but lowered the price target from $90 to $81. This indicates that while the analyst s…
Sep 21, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Monday's After-Market Session
This 8-K filing, presented as a Benzinga article, details the after-market stock performance of a selection of healthcare companies. The primary event disclosed is the price volati…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 92
AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate
AnaptysBio (ANAB) announced its Q2 financial results, reporting an adjusted EPS of $(0.11) which significantly beat the analyst estimate of $(0.46). Additionally, the company's sal…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target
The filing reports that HC Wainwright & Co. has reiterated its 'Buy' rating and maintained a $95 price target for AnaptysBio (ANAB). This action by an analyst signals continued con…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.